Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?

TheMotleyFool

0 0

Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?

CureVac (NASDAQ: CVAC) recently announced that Boehringer Ingelheim terminated a partnership on a messenger RNA lung cancer vaccine program. In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not this canceled deal spells trouble for other mRNA cancer vaccines in development.

Source Fool.com

Like: 0

CVAC

Share